How the practice of rheumatology differs in America and Europe.
Coding Corner: Incident-To
A 65-year-old female Medicare patient with rheumatoid arthritis sees a nonphysician provider for a followup visit.
Systemic Juvenile Idiopathic Arthritis
Changing treatment paradigms in the biologic era
Coding Corner: May’s Coding Challenge
A 54-year-old female with rheumatoid arthritis is seen by the rheumatologist for a follow-up visit.
Treatment Patterns and Trends for Spondylarthropathies
Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.
Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk
Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.
Ethics Forum: The Ethical Pitfalls of Clinical Trials
Your patient is deciding whether to enroll in a clinical trial at your institution and wants your advice about whether to participate.
The Mystery of IVIg
Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.
Where Will Kinase Inhibitors Fit into the RA Treatment Mix?
Presenters at “Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting, delved into some of the big questions that rheumatology faces with kinase inhibitor use.
Information on New Drug Approvals and Medication Safety
Rheumatology-related drug safety, approvals, and what’s in the pipeline.